[Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].
作者信息
Li Pei, Kang Xiaozheng, Chen Keneng
机构信息
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):496-500. doi: 10.3779/j.issn.1009-3419.2014.06.11.
Abstract
摘要
相似文献
1
[Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].ERCC1、RRM1和TS在非小细胞肺癌中的临床意义
Zhongguo Fei Ai Za Zhi. 2014 Jun 20;17(6):496-500. doi: 10.3779/j.issn.1009-3419.2014.06.11.
2
3
[Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer].[晚期非小细胞肺癌肿瘤组织及外周血淋巴细胞中RRM1和ERCC1基因的表达]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012 Sep;41(5):540-6. doi: 10.3785/j.issn.1008-9292.2012.05.012.
4
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.BRCA1、ERCC1、RRM1和RRM2在接受化疗的晚期非小细胞肺癌患者中的预后意义。
Tumour Biol. 2014 Dec;35(12):12679-88. doi: 10.1007/s13277-014-2592-7. Epub 2014 Sep 17.
5
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).非小细胞肺癌（NSCLC）中 DNA 修复和复制基因的表达：胸苷酸合成酶（TYMS）的作用。
BMC Cancer. 2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342.
6
Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.晚期非小细胞肺癌患者 ERCC1 和 RRM1 个体化化疗生存获益的初步迹象：来自个体患者分析的证据。
Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.
7
[Current translational research status of ERCC1 expression of
non-small cell lung cancer].[非小细胞肺癌ERCC1表达的当前转化研究现状]
Zhongguo Fei Ai Za Zhi. 2014 May;17(5):428-32. doi: 10.3779/j.issn.1009-3419.2014.05.12.
8
mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.RRM1、ERCC1和ERCC2的mRNA表达与人类肺癌细胞系对顺铂、卡铂和吉西他滨的化疗敏感性无关。
Respirology. 2008 Jun;13(4):510-7. doi: 10.1111/j.1440-1843.2008.01302.x.
9
ERCC1 and non-small-cell lung cancer.
N Engl J Med. 2007 Jun 14;356(24):2540; author reply 2540-1.
10
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.ERCC1信使核糖核酸的表达与接受铂类化疗的非小细胞肺癌的临床疗效相关。
Genet Mol Res. 2014 Dec 4;13(4):10215-22. doi: 10.4238/2014.December.4.16.
引用本文的文献
1
[Role of RRM1 in the Treatment and Prognosis of Advanced Non-small Cell Lung Cancer].[RRM1在晚期非小细胞肺癌治疗及预后中的作用]
Zhongguo Fei Ai Za Zhi. 2015 Jun;18(6):381-6. doi: 10.3779/j.issn.1009-3419.2015.06.09.
本文引用的文献
1
Cancer statistics, 2014.癌症统计数据，2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
2
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.胸苷酸合成酶的表达预测含培美曲塞化疗治疗非小细胞肺癌的临床结局：系统评价和荟萃分析。
Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26.
3
Folate binding site of flavin-dependent thymidylate synthase.黄素依赖性胸苷酸合成酶的叶酸结合位点。
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15722-7. doi: 10.1073/pnas.1206077109. Epub 2012 Sep 10.
4
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.胸苷酸合成酶和甲状腺转录因子 1 表达对接受培美曲塞为基础化疗的非鳞状非小细胞肺癌患者的意义。
J Thorac Oncol. 2011 Aug;6(8):1392-9. doi: 10.1097/JTO.0b013e3182208ea8.
5
Pharmacokinetic evaluation of pemetrexed.培美曲塞的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):919-28. doi: 10.1517/17425255.2011.587411. Epub 2011 May 21.
6
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.采用自动化定量原位分析技术检测 ERCC1 和 RRM1 在国际辅助性肺试验中的表达。
Am J Pathol. 2011 Jan;178(1):69-78. doi: 10.1016/j.ajpath.2010.11.029. Epub 2010 Dec 23.
7
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.核苷酸还原酶大亚基（RRM1）作为癌症患者的预测因子。
Lancet Oncol. 2011 Jul;12(7):693-702. doi: 10.1016/S1470-2045(10)70244-8. Epub 2010 Dec 14.
8
The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).核糖体核苷酸还原酶调节亚基 M1（RRM1）蛋白的免疫组化过表达是晚期非小细胞肺癌（NSCLC）患者接受基于吉西他滨化疗后生存时间更短的预测指标。
Lung Cancer. 2010 Nov;70(2):205-10. doi: 10.1016/j.lungcan.2010.02.005. Epub 2010 Mar 12.
9
First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.一线全身化疗治疗晚期非小细胞肺癌：系统评价。
J Thorac Oncol. 2010 Feb;5(2):260-74. doi: 10.1097/JTO.0b013e3181c6f035.
10
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.非小细胞肺癌：欧洲肿瘤内科学会（ESMO）关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:68-70. doi: 10.1093/annonc/mdp132.
Zotero 插件